Hasan Volkan Ege, Derman Başaran, Murat Gültekin, Nejat Özgül, Nurattin Boran, Sevgi Koç, Yaprak Üstün, Caner Çakır, Dilek Yüksel, Okan Oktar, Gökçen Ege, Abdurrahman Alp Tokalıoğlu, Mustafa Şahin, Yeşim Uçar, Fatih Kılıç, Okan Aytekin, Burak Ersak, Mehmet Ünsal, Özlem Moraloğlu Tekin, Çiğdem Kılıç, Özgür Koçak, Çağatayhan Öztürk, Salih Taşkın, Fırat Ortaç, Işın Üreyen, Tayfun Toptaş, Sevda Baş, Mehmet Ali Narin, Tolga Taşçı, Gökhan Uçar, Mehmet Ali Şendur, Burak Civelek, Doğan Uncu, Özgür Erdoğan, Muzaffer Sancı, Hakan Raşit Yalçın, İlker Selçuk, Taner Turan
{"title":"Recurrence of Adult Granulosa Cell Tumors: The Factors Affecting Secondary Recurrence and Survival After Recurrence.","authors":"Hasan Volkan Ege, Derman Başaran, Murat Gültekin, Nejat Özgül, Nurattin Boran, Sevgi Koç, Yaprak Üstün, Caner Çakır, Dilek Yüksel, Okan Oktar, Gökçen Ege, Abdurrahman Alp Tokalıoğlu, Mustafa Şahin, Yeşim Uçar, Fatih Kılıç, Okan Aytekin, Burak Ersak, Mehmet Ünsal, Özlem Moraloğlu Tekin, Çiğdem Kılıç, Özgür Koçak, Çağatayhan Öztürk, Salih Taşkın, Fırat Ortaç, Işın Üreyen, Tayfun Toptaş, Sevda Baş, Mehmet Ali Narin, Tolga Taşçı, Gökhan Uçar, Mehmet Ali Şendur, Burak Civelek, Doğan Uncu, Özgür Erdoğan, Muzaffer Sancı, Hakan Raşit Yalçın, İlker Selçuk, Taner Turan","doi":"10.7150/jca.127596","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Adult-type granulosa cell tumors (AGCTs) are rare ovarian neoplasms with a low overall incidence of recurrence, and also data on secondary recurrence and survival after relapse remain limited. This study aimed to identify factors associated with secondary recurrence and survival after recurrence in patients with recurrent AGCTs.</p><p><strong>Methods: </strong>This multicenter retrospective study included 52 patients with recurrent AGCTs identified among 484 patients treated between 2000 and 2023. Clinical characteristics, treatment modalities, and outcomes were analyzed, with a particular focus on factors associated with secondary recurrence and survival after first recurrence. Recurrence-free survival and overall survival after first recurrence (OS-FR) were evaluated using Kaplan-Meier analysis.</p><p><strong>Results: </strong>The mean follow-up duration was 99.2 ± 61.5 months. Secondary recurrence occurred in 17 patients (32.7%). A serum CA-125 level >35 U/mL at the time of first recurrence was significantly associated with an increased risk of secondary recurrence (p=0.01). Factors significantly associated with improved OS-FR included a CA-125 level ≤35 U/mL at initial diagnosis and at first recurrence, absence of residual disease following surgery for the first recurrence, and administration of salvage chemotherapy (all p<0.05). In subgroup analysis, salvage chemotherapy was associated with improved OS-FR in patients with residual disease or those who did not undergo surgery (p < 0.01), but not in patients who achieved complete cytoreduction (p = 0.67).</p><p><strong>Conclusions: </strong>Secondary recurrence remains a significant clinical challenge in AGCTs. Serum CA-125 levels, surgical outcomes at first recurrence, and the use of salvage chemotherapy may help management strategies in recurrent disease.</p>","PeriodicalId":15183,"journal":{"name":"Journal of Cancer","volume":"17 3","pages":"637-645"},"PeriodicalIF":3.4000,"publicationDate":"2026-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13003604/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.7150/jca.127596","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Adult-type granulosa cell tumors (AGCTs) are rare ovarian neoplasms with a low overall incidence of recurrence, and also data on secondary recurrence and survival after relapse remain limited. This study aimed to identify factors associated with secondary recurrence and survival after recurrence in patients with recurrent AGCTs.
Methods: This multicenter retrospective study included 52 patients with recurrent AGCTs identified among 484 patients treated between 2000 and 2023. Clinical characteristics, treatment modalities, and outcomes were analyzed, with a particular focus on factors associated with secondary recurrence and survival after first recurrence. Recurrence-free survival and overall survival after first recurrence (OS-FR) were evaluated using Kaplan-Meier analysis.
Results: The mean follow-up duration was 99.2 ± 61.5 months. Secondary recurrence occurred in 17 patients (32.7%). A serum CA-125 level >35 U/mL at the time of first recurrence was significantly associated with an increased risk of secondary recurrence (p=0.01). Factors significantly associated with improved OS-FR included a CA-125 level ≤35 U/mL at initial diagnosis and at first recurrence, absence of residual disease following surgery for the first recurrence, and administration of salvage chemotherapy (all p<0.05). In subgroup analysis, salvage chemotherapy was associated with improved OS-FR in patients with residual disease or those who did not undergo surgery (p < 0.01), but not in patients who achieved complete cytoreduction (p = 0.67).
Conclusions: Secondary recurrence remains a significant clinical challenge in AGCTs. Serum CA-125 levels, surgical outcomes at first recurrence, and the use of salvage chemotherapy may help management strategies in recurrent disease.
期刊介绍:
Journal of Cancer is an open access, peer-reviewed journal with broad scope covering all areas of cancer research, especially novel concepts, new methods, new regimens, new therapeutic agents, and alternative approaches for early detection and intervention of cancer. The Journal is supported by an international editorial board consisting of a distinguished team of cancer researchers. Journal of Cancer aims at rapid publication of high quality results in cancer research while maintaining rigorous peer-review process.